Abstract
Adamantiades-Behçet disease (ABD) is a distinct, chronic, relapsing systemic inflammatory disorder. ABD is not the typical autoinflammatory disease and should be viewed as a condition linking autoinflammation and autoimmunity classified among the primary systemic vasculitides. ABD exists worldwide, but it is more prevalent across the ancient trading route known as the “Silk Road”, i.e. in countries of the Mediterranean Basin, the Middle East and the Far East. The clinical spectrum is diverse, with significant differences in the prevalence of clinical manifestations between ethnic groups. Diagnosis is entirely clinical and in the absence of other explanations is based on the presence of recurring oral ulcerations (aphthous or herpetiform) at least three times in a 12-month period, plus at least any two of the following: recurrent genital aphthous ulceration or scarring, inflammation of the anterior and/or the posterior eye pole, skin lesions (erythema nodosum, pseudofolliculitis, papulopustular lesions or acneiform nodules in postadolescent patients not on corticosteroids) and a positive pathergy test (non-specific skin hyperreactivity in response to minor trauma). Intestinal, joint and central nervous system involvement and vascular thrombosis and formation of arterial aneurysms also frequently occur. Morbidity and mortality are significant; ocular involvement results in blindness if left untreated in more than 70% of those affected. Treatment should be individualized balancing the risks of therapy with the putative efficacy of a given approach. For self-limited manifestations, the aim is to control symptoms. The prompt use of immunosuppressive agents, including anti-TNF monoclonal antibodies, is mandatory for vital organ involvement.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arida A, Vaiopoulos G, Markomichelakis N, Kaklamanis P, Sfikakis PP. Are clusters of patients with distinct clinical expression present in Behçet’s disease? Clin Exp Rheumatol. 2009;27(2 Suppl 53):S48–51.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.
Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S149–55.
Burillo-Sanz S, Montes-Cano MA, García-Lozano JR, Ortiz-Fernández L, Ortego-Centeno N, García-Hernández FJ, Espinosa G, Graña-Gil G, Sánchez-Bursón J, Rosa Juliá M, Solans R, Blanco R, Barnosi-Marín AC, Gómez De la Torre R, Fanlo P, Rodríguez-Carballeira M, Rodríguez-Rodríguez L, Camps T, Castañeda S, Alegre-Sancho JJ, Martín J, González-Escribano MF. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: a next generation sequencing approach. Sci Rep. 2017;7(1):8453.
Criteria for diagnosis of Behcet’s disease: international study group for Behcet’s disease. Lancet. 1990;335:1078–80.
Curnow SJ, Pryce K, Modi N, Knight B, Graham EM, Stewart JE, Fortune F, Stanford MR, Murray PI, Wallace GR. Serum cytokine profiles in Behçet’s disease: is there a role for IL-15 in pathogenesis? Immunol Lett. 2008;121(1):7–12.
Dalghous AM, Freysdottir J. Fortune F Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35(6):472–5.
Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001;60(11):1074–6.
Elezoglou AV, Sfikakis PP, Vaiopoulos G, Kapsimali V, Kaklamanis PG. Serum levels of soluble TNF-alpha receptor-II (P75), circulating gamma delta T-cells and Adamantiades-Behçet’s disease activity. Adv Exp Med Biol. 2003;528:261–5.
Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP. Infliximab treatment-induced formation of autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S65–9.
Emmi G, Silvestri E, Bella CD, Grassi A, Benagiano M, Cianchi F, Squatrito D, Cantarini L, Emmi L, Selmi C, Prisco D, D'Elios MM. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease. Medicine (Baltimore). 2016;95(49):e5516.
Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis. 2000;59(8):622–5.
Gul A, Ohno S. HLA-B*51 and Behçet Disease. Ocul Immunol Inflamm. 2012;20:37–43.
Hatemi G, Fresko I, Tascilar K, Yazici H. Increased enthesopathy among Behçet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 2008;58(5):1539–45.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656–62.
Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y. Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.
Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–76.
Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuemmerle-Deschner J, Agostini H, Federici S, Arnoux A, Piedvache C. Ozen S; PEDBD group. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958–64.
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Hl Y. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.
Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Cantarini L. Iannone F Cytokine signatures in mucocutaneous and ocular Behçet’s disease. Front Immunol. 2017;8:200. https://doi.org/10.3389/fimmu.2017.00200. eCollection 2017.
Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–50.
Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593–7.
Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154(3):534–41.
Markomichelakis NN, Aissopou EK, Maselos S, Tugal-Tutkun I, Sfikakis PP. Biologic treatment options for retinal neovascularization in Behçet’s disease. Ocul Immunol Inflamm. 2017;12:1–7. https://doi.org/10.1080/09273948.2017.1332228. [Epub ahead of print].
McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297.
Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, Vera Recabarren M, Espinosa G, Jara Quezada J, Cervera R. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9:241–5.
Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, Song YW, Lee EB, Kitaichi N, Namba K, Horie Y, Takeno M, Sugita S, Mochizuki M, Bahram S, Ishigatsubo Y, Inoko H. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.
Özdemir FT, Demiralp EE, Aydın SZ, Atagündüz P, Ergun T, Direskeneli H. Immune and inflammatory gene expressions are different in Behçet’s disease compared to those in Familial Mediterranean Fever. Eur J Rheumatol. 2016;3(4):146–52.
Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis K, Karatzis E, Papaioannou TG, Ikonomidis I, Kaklamanis P, Mavrikakis M, Lekakis J. Interrelated modulation of endothelial function in Behcet’s disease by clinical activity and corticosteroid treatment. Arthritis Res Ther. 2007;9(5):R90.
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’ disease. Nat Genet. 2010;42:698–702.
Saadoun D, Wechsler B, Desseaux K, Le Thi HD, Amoura Z, Resche-Rigon M, Cacoub P. Mortality in Behcet’s disease. Arthritis Rheum. 2010;62:2806–12.
Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358:295–6.
Sfikakis PP. Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61(Suppl 2):ii51–3.
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140(5):404–6.
Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet’s disease: review and basis for recommendations. Rheumatology (Oxford). 2007;46:736–41.
Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, Tektonidou M, Markomichelakis N. Drug-free long-term remission in severe Behcet’s disease following withdrawal of successful anti-TNF treatment. Arthritis Rheumatol. 2017; https://doi.org/10.1002/art.40235. [Epub ahead of print].
Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, Takahashi M, Mochizuki M. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet’s disease. J Immunol. 2013;190(11):5799–808.
Vaiopoulos AG, Sfikakis PP, Kanakis MA, Vaiopoulos G, Kaklamanis PG. Gastrointestinal manifestations of Behçet’s disease: advances in evaluation and management. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S140–8.
Wu Z, Zhang S, Li J, Chen S, Li P, Sun F, Wen X, Zheng W, Zhang F, Li Y. Association between MEFV mutations M694V and M680I and Behçet’s disease: a meta-analysis. PLoS One. 2015;10(7):e0132704. https://doi.org/10.1371/journal.pone.0132704. eCollection 2015.
Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:148–55.
Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322:281–5.
Yazici H, Seyahi E, Yurdakul S. Behcet’s syndrome is not so rare: why do we need to know? Arthritis Rheum. 2008;58:3640–3.
Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades- Behcet’s disease. J Invest Dermatol. 2002;119:201–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sfikakis, P.P. (2019). Adamantiades-Behçet’s Disease. In: Efthimiou, P. (eds) Auto-Inflammatory Syndromes. Springer, Cham. https://doi.org/10.1007/978-3-319-96929-9_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-96929-9_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-96928-2
Online ISBN: 978-3-319-96929-9
eBook Packages: MedicineMedicine (R0)